Pharsight

1. List of Empaveli drug patents

^new

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9169307	APELLIS PHARMS	Potent compstatin analogs	Nov, 2027 (4 years from now)
US7888323	APELLIS PHARMS	Potent compstatin analogs	Dec, 2027 (4 years from now)
US7989589	APELLIS PHARMS	Compstatin analogs with improved activity	Dec, 2027 (4 years from now)
US10125171	APELLIS PHARMS	Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof	Aug, 2033 (10 years from now)
US10875893	APELLIS PHARMS	Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods	Nov, 2033 (10 years from now)
US10035822	APELLIS PHARMS	Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods	Nov, 2033 (10 years from now)
US11292815	APELLIS PHARMS	Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods	Nov, 2033 (10 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11040107	APELLIS PHARMS	Dosing regimens and related compositions and methods	Apr, 2038 (14 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	May 14, 2026
Orphan Drug Exclusivity (ODE)	May 14, 2028
M (M)	Feb 8, 2026

NCE-1 date: 2025-05-14

Market Authorisation Date: 14 May, 2021

Treatment: Treatment of adult patients with paroxysmal nocturnal hemoglobinuria (pnh) by administration of 1080 mg of pegcetacoplan; Treatment of adult patients with paroxysmal nocturnal hemoglobinuria (pnh) by ...

Dosage: SOLUTION;SUBCUTANEOUS

Strength	Dosage	Availability
1080MG/20ML (54MG/ML)	SOLUTION;SUBCUTANEOUS	Prescription

EMPAVELI family patents

United States

Japan

European Union

Australia

Canada

China

Spain

Israel

Hong Kong

Denmark

Russia

Brazil

Mexico

Portugal

Poland

Slovenia

Lithuania

Croatia

Hungary

Cyprus

Korea, Republic of

Norway

Austria

^new

2. List of Syfovre drug patents

^new

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9169307	APELLIS PHARMS	Potent compstatin analogs	Nov, 2027 (4 years from now)
US7888323	APELLIS PHARMS	Potent compstatin analogs	Dec, 2027 (4 years from now)
US7989589	APELLIS PHARMS	Compstatin analogs with improved activity	Dec, 2027 (4 years from now)
US10125171	APELLIS PHARMS	Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof	Aug, 2033 (10 years from now)
US11292815	APELLIS PHARMS	Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods	Nov, 2033 (10 years from now)
US10035822	APELLIS PHARMS	Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods	Nov, 2033 (10 years from now)
US10875893	APELLIS PHARMS	Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods	Nov, 2033 (10 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9056076	APELLIS PHARMS	Method of treating age-related macular degeneration comprising administering a compstatin analog	Oct, 2026 (3 years from now)
US8168584	APELLIS PHARMS	Methods of treating age-related macular degeneration by compstatin and analogs thereof	Apr, 2027 (3 years from now)

Exclusivity	Exclusivity Expiration
New Product (NP)	Feb 22, 2026
New Chemical Entity Exclusivity (NCE)	May 14, 2026

NCE-1 date: 2025-05-14

Market Authorisation Date: 17 February, 2023

Treatment: Treatment of geographic atrophy secondary to age-related macular degeneration by intravitreal administration of pegcetacoplan; Treatment of geographic atrophy secondary to age-related macular degenera...

Dosage: SOLUTION;INTRAVITREAL